Topics:
Hematologic Malignancies • Lymphoma • NCI-CCC Tumor Board Question • Hematology • UC Irvine • NCI-CCC Lymphoma Tumor Board Question
In light of the TRIANGLE data at ASH, how are you now approaching a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?
Are you adding ibrutinib? Should we add ibrutinib to NORDIC? Still referring to transplant?
Answer from: Medical Oncologist at Academic Institution
The TRIANGLE data presented by Dr. Dreyling on behalf of the European Mantle Cell Network are certainly provocative. Adding ibrutinib to induction pre-BEAM and maintenance post-BEAM (A+I) led to improved FFS compared to standard-of-care induction and maintenance (A). Not surprising, and doesn't tell...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The TRIANGLE study was a monumental trial led by the European MCL network. The study evaluated three arms R-CHOP/R-DHAP followed by ASCT, R-CHOP/R-DHAP + Ibrutinib (I) followed by ASCT + I (2 years), and R-CHOP/R-DHAP + I followed by I (2 years). The study demonstrated that the I-containing arm...